Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Basi, CA
Guriq Basi, Palo Alto, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080221306 | HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 09-11-2008 |
| 20080281082 | HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 11-13-2008 |
| 20090069544 | HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 03-12-2009 |
| 20110142823 | Humanized antibodies that recognize beta amyloid peptide - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies. | 06-16-2011 |
Guriqbal Basi, Palo Alto, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090144840 | Beta-secretase enzyme compositions and methods - Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease. | 06-04-2009 |
| 20090286281 | Glycosylation Variants of BACE - Human BACE polypeptides having modifications to the N-linked glycosylation sites including one or more of the following amino acid substitutions: S174I, N223A, N153Q and N354S. DNA sequences, vectors, and host cells for producing the polypeptides. Crystalline protein compositions formed from the purified polypeptides. Methods of screening for compounds that inhibit Aβ using the polypeptides. | 11-19-2009 |
Guriqbal S. Basi, Palo Alto, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080300206 | Alpha-Synuclein Kinase - The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase. | 12-04-2008 |
| 20090023158 | Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase - The invention provides assays and methods for determining the substrate specificity of gamma secretase inhibitors and for identifying substrate-selective (and substrate isoform-selective) inhibitors of gamma secretase. The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a site specific or substrate specific manner. The invention provides isolated polypeptide sequences comprising modified gamma secretase substrates, and polynucleotide sequences encoding the polypeptide sequences. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. | 01-22-2009 |
| 20090163594 | Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors - The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a substrate specific manner. The invention provides an isolated cell wherein the cell stably expresses APP and at least one gamma secretase substrate other than APP. The invention provides assays and methods comprising contacting a cell with gamma secretase and detecting production of Abeta, detecting production of intracellular domain (ICD), and detecting a signal from a reporter gene under transcriptional control of the ICD. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds. | 06-25-2009 |
| 20100143946 | ALPHA-SYNUCLEIN KINASE - The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase. | 06-10-2010 |